Top

Published in:

01-10-2020 | Cardiomyopathy | IM - ORIGINAL

Hyperuricemia: risk factor for thromboembolism in hypertrophic cardiomyopathy patients

Authors: Ziqiong Wang, Hang Liao, Xiaoping Chen, Sen He

Published in: Internal and Emergency Medicine | Issue 7/2020

Abstract

Hyperuricemia has been regarded as a risk factor for various cardiovascular diseases. However, few studies have evaluated its influence on thromboembolism in hypertrophic cardiomyopathy (HCM) patients. The purpose of the present study is to investigate the association between hyperuricemia and thromboembolism in a retrospective HCM cohort. A total of 447 adult HCM patients were enrolled in this study from December 2008 to May 2016. Uric acid levels were measured at baseline. Hyperuricemia was defined as blood uric acid level > 360 µmol/L for female patients and > 420 µmol/L for male patients, respectively. The association between hyperuricemia and thromboembolism was analyzed. During the follow-up period of 1786.8 person-years, 31 patients (6.9%) developed thromboembolic events. There was a higher thromboembolism incidence in patients with hyperuricemia than those with normouricemia (8.9% vs. 5.6%; unadjusted HR 2.35, 95% CI 1.16–4.78, P = 0.018). The association slightly increased after adjusting for potential confounders (HR 2.67, 95% CI 1.24–5.76, P = 0.013). Atrial fibrillation (AF) and left ventricular outflow tract obstruction played an interactive role in the relationship between hyperuricemia and thromboembolism with P for interaction of 0.011 and 0.007, respectively. Adjusted HRs of hyperuricemia were 8.99 (95% CI 2.23–36.29, P = 0.002) for thromboembolism in HCM patients with AF and 6.89 (95% CI 2.23–21.24, P = 0.001) in non-obstructive HCM patients. The association lost statistical significance among patients without AF and obstructive ones. Hyperuricemia significantly predicts future thromboembolism in HCM patients, especially in HCM patients with AF and non-obstructive HCM patients. Future studies are warranted for further evaluation.

Maron BJ (1997) Hypertrophic cardiomyopathy. Lancet 350:127–133. https://doi.org/10.1016/S0140-6736(97)01282-8CrossRefPubMed

Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308–1320. https://doi.org/10.1001/jama.287.10.1308CrossRefPubMed

Maron BJ, Olivotto I, Bellone P et al (2002) Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 39:301–307. https://doi.org/10.1016/S0735-1097(01)01727-2CrossRefPubMed

Choi YJ, Choi EK, Do HK et al (2018) Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: a nationwide population-based study. Int J Cardiol 273:130–135. https://doi.org/10.1016/j.ijcard.2018.08.038CrossRefPubMed

Haruki S, Minami Y, Hagiwara N (2016) Stroke and embolic events in hypertrophic cardiomyopathy: risk stratification in patients without atrial fibrillation. Stroke 47:936–942. https://doi.org/10.1161/STROKEAHA.115.012130CrossRefPubMed

Bos MJ, Koudstaal PJ, Hofman A et al (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study. Stroke 37:1503–1507. https://doi.org/10.1161/01.STR.0000221716.55088.d4CrossRefPubMed

Hozawa A, Folsom AR, Ibrahim H et al (2006) Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 187:401–407. https://doi.org/10.1016/j.atherosclerosis.2005.09.020CrossRefPubMed

Holme I, Aastveit AH, Hammar N et al (2009) Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 266:558–570. https://doi.org/10.1111/j.1365-2796.2009.02133.xCrossRefPubMed

Storhaug HM, Norvik JV, Toft I et al (2013) Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study. BMC Cardiovasc Disord. https://doi.org/10.1186/1471-2261-13-115CrossRefPubMedPubMedCentral

10.

Zamorano JL, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779. https://doi.org/10.1093/eurheartj/ehu284CrossRef

11.

He S, Wang Z, Cheem TH et al (2019) External validation of the model of thrombo-embolic risk in hypertrophic cardiomyopathy patients. Can J Cardiol. https://doi.org/10.1016/j.cjca.2019.05.035CrossRefPubMed

12.

Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 283:2404–2410CrossRef

13.

Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 16:233–271. https://doi.org/10.1093/ehjci/jev014CrossRefPubMed

14.

Zhu L, Wang J, Wang Y et al (2015) Plasma uric acid as a prognostic marker in patients with hypertrophic cardiomyopathy. Can J Cardiol 31:1252–1258. https://doi.org/10.1016/j.cjca.2015.02.018CrossRefPubMed

15.

Zhang C, Liu R, Yuan J et al (2016) Gender-related differences in the association between serum uric acid and left ventricular mass index in patients with obstructive hypertrophic cardiomyopathy. Biol Sex Differ. https://doi.org/10.1186/s13293-016-0074-xCrossRefPubMedPubMedCentral

16.

Ozylmaz S, Satlmolu MH, Gül M et al (2018) Evaluation of the association between serum uric acid level and the predicted risk score of sudden cardiac death in five years in patients with hypertrophic cardiomyopathy. Turk Kardiyol Dern Ars 46:111–120. https://doi.org/10.5543/tkda.2017.60094CrossRef

17.

Chao TF, Liu CJ, Chen SJ et al (2014) Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation—could it refine clinical risk stratification in AF? Int J Cardiol 170:344–349. https://doi.org/10.1016/j.ijcard.2013.11.011CrossRefPubMed

18.

Su HM, Lin TH, Hsu PC et al (2014) Association of hyperuricemia with cardiac events in patients with atrial fibrillation. Int J Cardiol 172:464–465. https://doi.org/10.1016/j.ijcard.2013.12.263CrossRefPubMed

19.

Tamariz L, Agarwal S, Soliman EZ et al (2011) Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 108:1272–1276. https://doi.org/10.1016/j.amjcard.2011.06.043CrossRefPubMedPubMedCentral

20.

Nyrnes A, Toft I, Njølstad I et al (2014) Uric acid is associated with future atrial fibrillation: an 11-year follow-up of 6308 men and women—the Tromsø study. Europace 16:320–326. https://doi.org/10.1093/europace/eut260CrossRefPubMed

21.

Kuwabara M, Niwa K, Nishihara S et al (2017) Hyperuricemia is an independent competing risk factor for atrial fibrillation. Int J Cardiol 231:137–142. https://doi.org/10.1016/j.ijcard.2016.11.268CrossRefPubMed

22.

Maharani N, Kuwabara M, Hisatome I (2016) Hyperuricemia and atrial fibrillation. Int Heart J 57:395–399. https://doi.org/10.1536/ihj.16-192CrossRefPubMed

23.

Maron BJ, Rowin EJ, Maron MS, Braunwald E (2017) Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored … until now. Am J Med 130:119–123. https://doi.org/10.1016/j.amjmed.2016.09.015CrossRefPubMed

24.

Pelliccia F, Pasceri V, Limongelli G et al (2017) Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol 243:379–384. https://doi.org/10.1016/j.ijcard.2017.06.071CrossRefPubMed

25.

Lu DY, Pozios I, Haileselassie B et al (2018) Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. J Am Heart Assoc 7:1–12. https://doi.org/10.1161/JAHA.117.006657CrossRef

Title: Hyperuricemia: risk factor for thromboembolism in hypertrophic cardiomyopathy patients
Authors: Ziqiong Wang
Hang Liao
Xiaoping Chen
Sen He
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keywords: Cardiomyopathy
Atrial Fibrillation
Published in: Internal and Emergency Medicine / Issue 7/2020
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-020-02275-6

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Hyperuricemia: risk factor for thromboembolism in hypertrophic cardiomyopathy patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2020

CTA-occult traumatic carotid blowout injury

The HEART score as a prognostic tool for revascularization: comment

Orthostatic hypotension among elderly patients in Italian internal medicine wards: an observational study—comment

Infections in out-of-hospital and in-hospital post-cardiac arrest patients: comment

Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments

Epidemiology of right ventricular systolic dysfunction in patients with sepsis and septic shock in the emergency department

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page